GT Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
GT Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
GT Biopharma Inc GTBP.OQ reported a quarterly adjusted loss of 12 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -52 cents. The lone analyst forecast for the quarter was for a loss of 8 cents per share.
Reported revenue was zero; analysts expected zero.
GT Biopharma Inc's reported EPS for the quarter was a loss of 12 cents.
The company reported a quarterly loss of $4.59 million.
GT Biopharma Inc shares had fallen by 39.3% this quarter and lost 62.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for GT Biopharma Inc is $3.00, about 90.1% above its last closing price of $0.30
This summary was machine generated from LSEG data August 14 at 01:47 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.08 | -0.12 | Missed |
Mar. 31 2026 | -0.08 | -0.11 | Missed |
Dec. 31 2025 | -0.22 | -4.84 | Missed |
Sep. 30 2025 | -0.38 | -0.79 | Missed |